for people living with neurological disorders
Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.
This site will remain live until Q4 2024 as we transition content to our new site.
for people living with neurological disorders
About Us
Our goal is to prevent the progression of disease to enable the progression of the person.
Our Focus
Up to 1 billion people suffer from neurological disorders. The strength of our commitment comes from our personal connections to this cause.
Advances in genetic medicines have validated that AAVs can deliver therapeutic genes directly to the CNS in a well-tolerated and effective manner.
We are driven by a belief that meaningful discovery is born from curiosity, collaboration, and compassion.
Our passionate team is built on a rare and powerful foundation of expertise backed by knowledgeable investors.
View All